MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Vilya
Organization & Developments: Vilya
Parents
Vilya
Children
2022: Arch builds bridge to new class of medicines, leading $50M investment in the AI-enabled Vilya
The Company’s proprietary platform, powered by advanced machine learning, taps into uncharted chemical space to design de novo molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies
The Seattle-based biotech plans to design novel artificial molecules with customized biologic-like properties that can hit difficult-to-drug therapeutic targets in a broad set of indications
Vilya is a computational biotechnology company creating a novel class of medicines to precisely target disease biology.
Vilya’s ability to precisely design membrane permeable molecules with high structural accuracy opens the door to a new class of medicines that combine the advantages of traditional small molecule drugs and larger protein-based therapeutics
Jumps
Finance & Acquisitions: Vilya
Key People: Vilya